Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial symbols : Gild save search
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: -100.0%
H: NaN%
C: Infinity%
GILD | $66.95 0.29% 0.28% 5.6M
|
Health Technology
|
| O: 0.5%
H: 0.83%
C: 0.28%
CTXR | $0.7329 -2.85% -2.93% 1.3M
|
Health Technology
|
| O: 2.33%
H: 2.28%
C: -4.23%
hope treatment pharmaceuticals city for car-t trial
Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH
Published: 2023-12-08 (Crawled : 21:00) - prnewswire.com
ACLX | $52.0 0.68% 0.67% 430K
|
| Email alert
Add to watchlist
GILD | $66.95 0.29% 0.28% 5.6M
|
Health Technology
| Email alert
Add to watchlist
expansion trial
Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program
Published: 2023-10-18 (Crawled : 11:00) - biospace.com/
GILD | $66.95 0.29% 0.28% 5.6M
|
Health Technology
|
| O: -0.01%
H: 0.3%
C: -0.99%
europe sciences hiv program trial
Lyndra Therapeutics Announces Leadership Changes, Update on Pivotal Trial Progress
Published: 2023-07-17 (Crawled : 13:20) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: 4.62%
H: 0.0%
C: -1.54%
GILD | $66.95 0.29% 0.28% 5.6M
|
Health Technology
|
| O: -0.67%
H: 1.42%
C: 1.06%
update trial therapeutics
Lyndra Therapeutics Doses First Clinical Trial Participant in Pivotal Study of Oral Weekly Risperidone (LYN-005) for Schizophrenia and Schizoaffective Disorder
Published: 2023-05-09 (Crawled : 15:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: -0.66%
H: 0.0%
C: 0.0%
GILD | $66.95 0.29% 0.28% 5.6M
|
Health Technology
|
| O: -0.36%
H: 1.23%
C: 0.63%
lyn-005 schizophrenia trial therapeutics study
Kite’s Tecartus® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Published: 2023-02-09 (Crawled : 13:00) - biospace.com/
GILD | $66.95 0.29% 0.28% 5.6M
|
Health Technology
|
| O: 0.19%
H: 0.9%
C: -0.35%
tecartus t-cell leukemia trial therapy
Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn’s disease
Published: 2023-02-08 (Crawled : 00:00) - globenewswire.com
GILD | $66.95 0.29% 0.28% 5.6M
|
Health Technology
|
| O: 0.19%
H: 0.9%
C: -0.35%
GLPG | News | $29.09 0.03% -0.14% 80K
|
Health Technology
|
| O: -8.03%
H: 0.95%
C: 0.75%
disease topline trial results
Strata Oncology Announces Addition of Gilead as Strata PATH Trial Collaborator
Published: 2023-01-18 (Crawled : 14:20) - prnewswire.com
GILD | $66.95 0.29% 0.28% 5.6M
|
Health Technology
|
| O: -0.46%
H: 0.12%
C: -1.51%
trial
Jounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical Trial data at the European Society of Medical Oncology Immuno-Oncology (ESMO - IO) Annual Congress
Published: 2022-12-08 (Crawled : 13:00) - globenewswire.com
JNCE | $1.88 -2.59% -1.85% 0
|
Health Technology
|
| O: 1.82%
H: 1.52%
C: -7.91%
GILD | $66.95 0.29% 0.28% 5.6M
|
Health Technology
|
| O: 0.09%
H: 1.98%
C: 1.82%
medical trial therapeutics phase 1
Jounce Therapeutics Reports Results from Phase 2 Randomized SELECT Trial Testing 2 Different Doses of Vopratelimab in TISvopra Biomarker-Selected Patients
Published: 2022-08-30 (Crawled : 13:00) - biospace.com/
JNCE | $1.88 -2.59% -1.85% 0
|
Health Technology
|
| O: -20.58%
H: 0.0%
C: 0.0%
GILD | $66.95 0.29% 0.28% 5.6M
|
Health Technology
|
| O: 0.1%
H: 0.29%
C: -0.02%
trial therapeutics results phase 2
Kronos Bio Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Lanraplenib in Combination with Gilteritinib in Acute Myeloid Leukemia
Published: 2022-08-22 (Crawled : 13:00) - biospace.com/
KRON | $0.9714 -3.82% -3.97% 170K
|
Health Technology
|
| O: -1.64%
H: 1.19%
C: -4.53%
GILD | $66.95 0.29% 0.28% 5.6M
|
Health Technology
|
| O: -0.2%
H: 0.06%
C: -1.3%
leukemia trial acute myeloid leukemia phase 2b
Lyndra Therapeutics Doses First Clinical Trial Participant in Study of Oral Biweekly Ivermectin (LYN-163) as a Tool in the Fight to Eradicate Malaria
Published: 2022-06-09 (Crawled : 14:00) - biospace.com/
GILD | $66.95 0.29% 0.28% 5.6M
|
Health Technology
|
| O: -0.14%
H: 0.0%
C: 0.0%
lyn-163 trial therapeutics malaria
G1 Therapeutics Announces Initiation of New Phase 2 Trial of Trilaciclib in Combination with the Antibody-Drug Conjugate (ADC)
Published: 2021-11-29 (Crawled : 13:00) - biospace.com/
GILD | $66.95 0.29% 0.28% 5.6M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
GTHX | $4.1 -0.24% -0.24% 480K
|
Health Technology
|
| O: 0.75%
H: 0.82%
C: -6.28%
phase 2 trilaciclib antibody drug trial therapeutics
G1 Therapeutics Announces Initiation of New Phase 2 Trial of Trilaciclib in Combination with the Antibody-Drug Conjugate (ADC), Trodelvy® (Sacituzumab Govitecan-Hziy)
Published: 2021-11-29 (Crawled : 12:00) - globenewswire.com
GILD | $66.95 0.29% 0.28% 5.6M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
GTHX | $4.1 -0.24% -0.24% 480K
|
Health Technology
|
| O: 0.75%
H: 0.82%
C: -6.28%
trodelvy phase 2 trilaciclib antibody drug trial therapeutics
Gilead Announces Clinical Trial Collaboration With Merck to Evaluate Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) in Patients With First-Line Metastatic Triple-Negative Breast Cancer
Published: 2021-10-28 (Crawled : 22:00) - biospace.com/
GILD | $66.95 0.29% 0.28% 5.6M
|
Health Technology
|
| O: -0.1%
H: 1.44%
C: 0.96%
collaboration cancer breast cancer trial keytruda
Vir Biotechnology Presents New Clinical Data from Ongoing Trials of VIR-2218 and VIR-3434 in Patients with Chronic Hepatitis B Virus Infection at the International Liver Congress 2021
Published: 2021-06-25 (Crawled : 13:00) - globenewswire.com
VIR | $8.11 2.01% 1.97% 1.1M
|
Health Technology
|
| O: -0.52%
H: 1.36%
C: -7.74%
GILD | $66.95 0.29% 0.28% 5.6M
|
Health Technology
|
| O: -0.06%
H: 1.28%
C: 1.1%
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: 0.26%
H: 1.5%
C: 0.72%
hepatitis ongoing biotech technology iot liver trial injection infections chronic hepatitis b
Jounce Therapeutics Presents Trial in Progress Posters on the INNATE and SELECT Clinical Trials at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
Published: 2021-06-04 (Crawled : 13:00) - globenewswire.com
JNCE | $1.88 -2.59% -1.85% 0
|
Health Technology
|
| O: 0.0%
H: 1.63%
C: -2.14%
GILD | $66.95 0.29% 0.28% 5.6M
|
Health Technology
|
| O: 0.47%
H: 1.17%
C: 0.96%
clinical trials trial
Jounce Therapeutics to Present Trial in Progress Posters on the Phase 1 INNATE and the Phase 2 SELECT Clinical Trials at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
Published: 2021-04-28 (Crawled : 12:15) - globenewswire.com
JNCE | $1.88 -2.59% -1.85% 0
|
Health Technology
|
| O: -0.3%
H: 0.3%
C: -3.8%
GILD | $66.95 0.29% 0.28% 5.6M
|
Health Technology
|
| O: 0.03%
H: 0.02%
C: -0.39%
phase 2 clinical trials phase 1 trial phase 3
NeuroRx Announces Zyesami™ (Aviptadil) Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir
Published: 2021-04-06 (Crawled : 06:00) - prnewswire.com
GILD | $66.95 0.29% 0.28% 5.6M
|
Health Technology
|
| O: -0.51%
H: 0.77%
C: 0.35%
trial aviptadil
Everest Medicines Announces China NMPA Approval of Clinical Trial Application to Evaluate Trodelvy® in a Phase 2 Basket Trial for a Variety of Cancers with High TROP-2 Expression
Published: 2021-03-31 (Crawled : 03:00) - prnewswire.com
GILD | $66.95 0.29% 0.28% 5.6M
|
Health Technology
|
| O: -0.24%
H: 0.0%
C: -1.09%
phase 2 china cancer trial approval
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.